Urothelial Carcinoma
📧 Sign up to get email alerts when something new happens for Urothelial Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-24Clinical Trial Update: Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors [Phase 1, Phase 2]
Clinical trial update on TT-00420 tablets with toripalimab for advanced urological tumors (Phase 1/2) with conditions including clear cell r…
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors [Phase 2]
Phase 2 trial evaluating checkpoint inhibition in combination with external beam radiotherapy for solid tumors; study is completed.
-
FDA approval · 2024-01-19FDA Approved: BALVERSA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for BALVERSA (erdafitinib) submitted by Janssen Products LP.
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) [Phase 1, Phase 2]
Phase 1/2 trial SEASTAR evaluating rucaparib in combination with other anticancer agents in solid tumors; study terminated with results post…
-
CLINICAL_TRIALS trial_result · 2024-01-09Clinical Trial Update: Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma [Phase 2]
A Phase 2 trial evaluating a neoadjuvant PD-1 monoclonal antibody in cisplatin-ineligible high-risk upper urinary tract urothelial carcinoma…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-12-21Clinical Trial Update: A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma [Phase 2]
A Phase 2 trial evaluating RC48-ADC in combination with Cadonilimab (AK104) for HER2-expressing locally advanced or metastatic urothelial ca…
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma [Phase 3]
Phase 3 trial evaluating RC48-ADC plus toripalimab for first-line urothelial carcinoma (HER2-expressing). Status: recruiting.
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer [Phase 2]
Phase 2 trial update for RC48-ADC in HER2-negative urothelial cancer has completed.
-
FDA label_change · 2023-12-15FDA Approved: PADCEV EJFV — Supplemental Application (SEAGEN INC.)
FDA supplemental application submitted for PADCEV EJFV (enfortumab vedotin) by Seagen.
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma [Phase 3]
Phase 3 trial evaluating atezolizumab as a standalone therapy and in combination with platinum-based chemotherapy for untreated locally adva…
-
CLINICAL_TRIALS trial_result · 2023-11-27Clinical Trial Update: A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer [Phase 2]
Phase II open-label trial evaluating RC48-ADC in HER2-overexpressing locally advanced or metastatic urothelial cancer completed.
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma [Phase 2]
Phase 2 trial evaluating first-line everolimus with or without paclitaxel in cisplatin-ineligible advanced urothelial carcinoma was terminat…
-
CLINICAL_TRIALS trial_result · 2023-10-31Clinical Trial Update: Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) [Phase 3]
Phase 3 trial evaluating first-line pembrolizumab in combination with lenvatinib for urothelial carcinoma in cisplatin-ineligible or platinu…
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer [Phase 1, Phase 2]
Clinical trial update on erdafitinib in participants with metastatic or locally advanced urothelial carcinoma (Phase 1/2); results have been…
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: Derazantinib and Atezolizumab in Patients With Urothelial Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating derazantinib with atezolizumab in urothelial carcinoma has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations [Phase 2]
Phase 2 trial updating activity of molecularly matched targeted therapies across select tumor types based on genomic alterations; study comp…
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: A Study of a Personalized Neoantigen Cancer Vaccine [Phase 1, Phase 2]
Clinical trial update for a personalized neoantigen cancer vaccine completed across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma [Phase 2]
Phase 2 trial evaluating atezolizumab plus chemotherapy after progression on PD-1/PD-L1 in cisplatin-ineligible advanced urothelial carcinom…
-
CLINICAL_TRIALS trial_result · 2023-08-24Clinical Trial Update: A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma [Phase 2]
Phase 2 study evaluating sitravatinib combined with PD-(L)1 inhibitors in advanced or metastatic urothelial carcinoma; the trial is terminat…
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Evaluation of NanoDoce® in Participants With Urothelial Carcinoma [Phase 1, Phase 2]
Phase 1/2 trial investigating NanoDoce® in urothelial carcinoma and bladder cancer has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating MAGE-A1-specific T cell receptor-transduced autologous T-cells with atezolizumab for metastatic triple-n…
-
CLINICAL_TRIALS trial_result · 2023-07-07Clinical Trial Update: A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer [Phase 2]
Phase 2 clinical trial evaluating ONM-100 as an intraoperative fluorescence imaging agent for cancer detection has completed enrollment with…
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma [Phase 2]
Phase 2 trial update for Utidelone in metastatic urothelial carcinoma is currently labeled as unknown status.
-
CLINICAL_TRIALS trial_result · 2023-05-26Clinical Trial Update: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma [Phase 2]
A Phase 2 clinical trial evaluating QLF31907 for safety and efficacy in advanced melanoma and urothelial carcinoma is ongoing with status cu…
-
FDA label_change · 2023-04-18FDA Approved: PADCEV EJFV — Supplemental Application (SEAGEN INC.)
FDA notes a supplemental application for PADCEV EJFV (enfortumab vedotin) from Seagen, likely seeking labeling changes or expansion of the a…